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Purpose or Objective: In radiotherapy of head and neck 
cancer the central nervous system is the dose limiting factor. 
Late side effects may occur which severely impair the 
patient’s quality of life. Thus, to improve the therapeutic 
ratio, radioprotective drugs receive increasing interest. In 
the optimal case, they could protect the normal central 
nervous system without influencing the tumor response to 
irradiation. A lot of studies using various approaches with 
e.g. melatonin, pentoxifylline, growth factors, Amifostine or 
Angiotensin converting enzymes inhibitors (ACEi) were 
performed focusing on mitigation or, ideally, on protection 
from late side effect in central nervous system (brain, optic 
nerve or spinal cord). 
 
Material and Methods: Within our study the impact of ACEi 
Ramipril on prevention from the late side effect radiation-
induced myelopathy (forelimb paresis grade II) was tested. 
The cervical spinal cord of female Sprague Dawley rats was 
irradiated with either 6 MeV photons or carbon ions (12C-ion) 
(a linear energy transfer (LET) of 45 keV/µm and a 6 cm 
spread-out Bragg Peak was used). Immediately after 
irradiation (RT) Ramipril (2 mg/kg/day) was given via the 
drinking water for 300 days. A total of four groups were used: 
(1) photon RT + Ramipril (n = 24), (2) photon RT only (n = 20), 
(3) 12C-ion RT + Ramipril (n = 20) and (4) 12C-ion RT only (n = 
20). For each group a complete dose-response curve after 
single dose irradiation was established and TD50-values (dose 
at 50% complication probability) were determined for the 
development of paresis grade II within 300 days. 
 
Results: Preliminary analysis of the data shows no marked 
shift of the TD50-values related to administration of Ramipril 
after 12C-ion or photon RT, however, a prolongation of 
latency time for both irradiation modalities was found. At a 
dose level of 21 Gy the minimum latency time after 12C-ion 
RT was 160 d compared to 191 d after 12C-ion RT + Ramipril 
administration. Whereas, at a dose level of 26 Gy the 
minimum latency time after photon RT was 191 d compared 
to 225 d after photon RT + Ramipril administration. Overall 
the latency time after 12C-ion RT was shorter compared to 
photon RT. 
 
Conclusion: Ramipril administration after 12C-ion or photon 
RT exhibits a prolongated latency time. However, to find an 
ideal radiomitigator further examinations of the underlying 
pathological mechanisms leading to radiation-induced 
myelopathy are necessary. Additionally, since it is unclear 
how Ramipril interfers the pathological mechanism(s) of 
radiation-induced damage, it is important to understand the 
underlying mechanism. Thereby it would be possible to 
compensate potential weak points in inhibition by 
combination with other compounds. 
 
PO-0991  
p53 and in vitro radiation response of fibroblasts from RT-
sensitive and -resistant patients 
C. Herskind
1Universitaetsmedizin Mannheim- Medical Faculty Mannheim- 
Heidelberg University, Department of Radiation Oncology, 
Mannheim, Germany 
1, O. Nuta2, N. Somaiah3, S. Boyle3, M.L.K. Chua4, 
L. Gothard3, K. Rothkamm5, J. Yarnold3 
2Public Health England, Centre for Radiation- Chemical and 
Environmental Hazards, Chilton, United Kingdom 
3Institute of Cancer Research, Division of Radiotherapy and 
Imaging, Sutton, United Kingdom 
4National Cancer Centre- Duke-NUS Graduate Medical School, 
Division of Radiation Oncology, Singapore, Singapore 
5Department of Radiotherapy and Radiation Oncology, 
University Medical Center Hamburg-Eppendorf, Hamburg, 
Germany 
 
Purpose or Objective: To test the association between the 
molecular and functional radiation response of fibroblasts in 
vitro and breast cancer patients' risk of late reaction after 
radiotherapy. 
 
Material and Methods: Fibroblast cultures were established 
by outgrowth from biopsies taken with informed consent from 
selected breast cancer patients with minimal (RT-resistant, 
n=15) or marked breast changes (RT-sensitive, n=19) after 
breast conserving therapy. The clinical risk of RT- sensitive 
patients was further ranked according to severity relative to 
external risk factors. Early-passage cultures were irradiated 
in vitro with 4Gy or sham irradiated. Molecular markers p53, 
p21/CDKN1A, p16/CDKN2A, α-sma, and Ki-67, were detected 
by immunofluorescence microscopy at 2h, 2 and 6 days after 
irradiation (IR). Plating efficiency (PE) and surviving fraction 
after 4 Gy (SF4) were determined by the colony formation 
assay. Non-parametric analysis of differences between 
fibroblasts from RT-sensitive and RT-resistant patients was 
performed with the Wilcoxon/Mann-Whitney test, and 
correlations using the Spearman's ρ rank correlation test. 
 
Results: The basal level of p53 without irradiation was 
significantly higher in fibroblast cultures from RT-sensitive 
relative to RT-resistant patients (P=0.02). p53 was 
upregulated 2h - 2 days after IR in all cells but decayed more 
slowly on day 6 in fibroblasts from RT-sensitive patients. 
Further, explorative analysis showed strong early 
upregulation of p53 2h after irradiation in fibroblasts from 
high-risk patients (P=0.002). RT sensitivity showed no 
significant correlation with p21/CDKN1A, p16/CDKN2A, a-
sma, and Ki-67, or functional endpoints, PE and SF4. 
However, proliferation activity (Ki-67 index) appeared to 
have a confounding influence on the effect of p53. Thus risk 
was correlated with basal levels of p53 (P<0.001) in 
unirradiated cultures with lower Ki-67 whereas it correlated 
with early upregulation at 2h (P<0.001) in cultures with 
higher Ki-67. Furthermore, correlations of p21/CDKN1A with 
p53 or p16/CDKN2A were markedly different in fibroblasts 
from RT sensitive and RT-resistant patients. 
 
Conclusion: In this cohort, patient selection was performed 
to enhance the contrast between RT-resistant and RT-
sensitive patients, including rare patients with severe late 
reaction. p53 levels in fibroblast cultures in vitro were 
significantly correlated with the risk of developing late breast 
changes after radiotherapy, and high-risk patients' fibroblasts 
showed strong early upregulation of p53 after irradiation 
which depended on the proliferation index. We suggest that a 
relation between p53 and the risk of late reaction exists in a 
subgroup of RT-sensitive patients, possibly via enhanced 
genetic instability and partial dysregulation of the DNA 
damage response. 
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Purpose or Objective: Rectal bleeding after radiation 
therapy (RT) for prostate cancer has been observed in up to 
40% of patients and it is mainly due to multiple rectal 
angiectasias developed after RT. Soon after the beginning of 
RT, there is an acute mucosal reaction that can evolve into a 
more severe condition with prominent vascular involvement, 
evidence of vasculitis, arteriolar thrombosis and subsequent 
ischemia and angiogenesis. Recently, attention to the role of 
hypoxia has contributed to the understanding of radiation-
induced late normal tissue response. Under hypoxic 
conditions, the diverse hypoxia-driven genes (e.g., VEGF) are 
regulated by a transcriptional factor, hypoxia-inducible 
factor-1 (HIF-1). In vivo and in vitro studies have shown that 
the HIF-1 expression increased soon after irradiation, 
reaching the highest level after 30 days and preceding the 
expression of VEGF.  
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Aim of this prospective study is to evaluate the expression of 
HIF-1 after RT and correlate it with the development of 
rectal mucosal angiectasias and bleeding.  
 
Material and Methods: Patients with histological proof of 
prostate cancer without distant metastases, undergoing a 
standard course of external beam radiation therapy (3D-RT), 
were considered eligible. Each patient underwent a 
rectosigmoidoscopy with bioptic sampling prior to and one 
month and one year after RT. The development of rectal 
mucosal angiectasias was graded according to the Vienna 
Rectoscopy Score (VRS). HIF-1 was evaluated by 
immunohistochemistry and western blot analysis; the mean 
number of blood vessels per field was also assessed. 
Radiation-induced side effects (e.g. rectal bleeding) were 
recorded during follow-up visits.  
 
Results: Thirty-one patients were enrolled (median age 72 
years, IQR 67-75). After the end of a median follow-up of 
19.8 months (IQR 18.4-20.9), 10 patients (32.3%) developed 
rectal bleeding needing intervention. All these patients 
presented a grade II or III VRS (p=0.03). The difference in the 
mean number of blood vessels between bleeders and not 
bleeders was not significantly different (p=0.47). The 
expression of HIF1 in bleeding patients was down regulated in 
2 cases, unchanged in 3 and up regulated in 4 cases (p>0.99); 
in one case it was not feasible to determine the expression. 
There was no correlation between the expression of HIF1 and 
the VRS.  
 
Conclusion: The expression of HIF1 does not correlate with 
the development of rectal mucosal angiectasias and bleeding 
in patients irradiated for prostate cancer. 
 
Poster: Radiobiology track: Biomarkers and biological 
imaging  
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Purpose or Objective: Subventricular zone-infiltrating (SVZ-
infiltrating) glioblastomas (GBMs) with subependymal spreads 
along ventricle walls are associated with decreased patient 
survival. The heterogeneity in patient survival and recurrence 
patterns of GBM with SVZ infiltration might be related to 
neuronal therapy resistant stem cells, located in the SVZ. It 
has not been systematically investigated if specific molecular 
genetic patterns of SVZ-infiltrating GBMs exist, and therefore 
are responsible for the unfavorable course after 
chemoradiation. 
 
Material and Methods: The current study assessed the 
molecularbiologic profile of 55 primary GBM cases that 
underwent chemoradiation. GBMs with SVZ infiltration and 
subependymal tumor spread (n = 24; 43.6 %) and peripherally 
located GBMs (n = 31; 56.4 %) were included. Genome 
methylation patterns were determined and copy number 
profiling was performed using an Illumina Infinium 
HumanMethylation450K (450K) Array, and the prognostic 
influence on progression and survival was evaluated. 
 
Results: The majority of patients showed the characteristics 
of a “classic” GBM subtype, independent of the tumor 
localization in regard of the SVZ, demonstrating a 
chromosome 7 gain and chromosome 10 loss, as well as 
deletion of Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) 
and amplification of Epidermal Growth Factor Receptor 
(EGFR). Second, RTK I subtype, showing Platelet-Derived 
Growth Factor Receptor Alpha (PDGFRA) amplifications, 
could be detected equally in both groups. However, SVZ-
infiltrating GBMs with subependymal spreading showed a 
decreased overall survival (OS) compared to their peripheral 
counterparts. 
 
 
 
Figure: Genome wide copy number profiling of a classic 
primary gliolblastoma with chromosome 7 gain and 
chromosome 10 loss  
 
Conclusion: Genome methylation patterns were distributed 
independently of tumor localization in regard of the SVZ, 
suggesting that the biological entities in both GBM groups are 
identical. However, survival rates of GBMs with proximity to 
the SVZ were inferior and therefore the central localization 
seems to be responsible for the poor clinical courses. 
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Purpose or Objective: Evidence to support a role for the 
antidiabetic drug metformin in the prevention and treatment 
of cancer has emerged over the last decade. In particular, 
recent studies demonstrate that metformin enhances tumor 
response to radiation in experimental models. Metformin may 
therefore be of utility for nondiabetic cancer patients 
treated with radiation therapy. Despite being in clinical use 
for almost 60 years, the underlying mechanisms for 
metformins action remain elusive. We have therefore applied 
a novel PET-tracer, [11C]-metformin, to determine the 
uptake mechanism and elimination of the drug in vitro and in 
vivo. 
 
Material and Methods: To verify transporter-mediated 
uptake of metformin in tumor cells, a selection of cell lines 
were incubated with [11C]-metformin in the absence or 
presence of blocking unlabelled metformin. Two tumor 
models A549 (lung) and SiHa (cervix) was chosen for in vivo 
experiments. Mice bearing subcutaneous tumors in the lower 
back were administered ~10 MBq [11C]-metformin and 
dynamically PET scanned for 90 minutes. As a “proof of 
principle” experiments using PET/CT with [11C]-metformin 
organ specific uptake of [11C]-metformin was determined in 
healthy humans. Dynamic whole-body PET was performed on 
four healthy volunteers (2 male). Two minutes before scan 
start, a bolus injection of ~200 MBq [11C]-metformin was 
injected and five consecutive whole-body scans with 
increasing frame durations were obtained: 1, 1.5, 2, 2.5 and 
3 minutes per bed position. Time intervals for the PET scans 
were 2-8, 9-18, 19-32, 33-48 and 49-67 minutes (see figure 
1). Source organs for the dosimetry calculations were the 
liver, kidneys, salivary glands and the bladder. 
Results: In vitro metformin uptake varied widely but a high 
and inhibitable uptake was observed in A549 and SiHa cells. 
